Welcome to BioSeeker Group!

Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Additional Information

Published Date Dec 19, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 301
PDF Fact Sheet View Fact Sheet for the report Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis.

    To find out more about Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Not surprisingly, an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved.

This report aims to analyze the current and future potential of colorectal cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.
This report is written for you to identify your competition and understand which targeting strategies are at work within colorectal cancer drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the colorectal cancer field and identified 120 drug targets belonging to 156 drugs. This report, Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs.

In the report, BioSeeker reports on 105 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 156 colorectal cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of colorectal cancer drugs. No less than 231 target-target interactions were recognized among and between 87 of the 120 included colorectal cancer drug targets.

Why You Should Own Your Own Copy of this Report:
* 300 pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
* A 156 colorectal cancer drugs analysis, under development by 95 investigators
* 120 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other colorectal cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
* A unique drug target combination breakdown of colorectal cancer drugs into R&D approaches
* Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
* Pathway profiling of colorectal cancer drug targets
* Compound strategies based on sub-cellular localization of drug targets
* Expression levels of identified drug targets in malignant colorectal cancer tissue
* Structure based drug design in colorectal cancer
* Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
* Who are working on sequels to blockbuster drugs?
* Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 4.1 List of Figures
4.2 List of Tables
5 How to Use this Report
6 Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer Drug Targets
7 The Cancer Genome Project and Colorectal Cancer Targets
7.1 Colorectal Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
8 Expression Levels of Identified Drug Targets in Colorectal Cancer Tissue
9 Pathway Analysis of Colorectal Cancer Drugs
10 Target-Target Interactions among Identified Colorectal Cancer Targets
11 Structure-based Drug Design in Colorectal Cancer is Stimulated by Available Structure Data on Biological Targets
12 Drug Target Profiles of Colorectal Cancer Drugs
12.1.1 Carboxy-lyase Activity Targets
12.1.2 Catalytic Activity Targets
12.1.3 Cell Adhesion Molecule activity Targets
12.1.4 Cofactor Binding Targets
12.1.5 Complement Activity Targets
12.1.6 Cysteine-Type Peptidase Activity Targets
12.1.7 Cytokine Activity Targets
12.1.8 DNA Binding Targets
12.1.9 DNA Topoisomerase Activity Targets
12.1.10 DNA-Directed DNA Polymerase Activity Targets
12.1.11 DNA-Methyltransferase Activity Targets
12.1.12 G-Protein Coupled Receptor Activity Targets
12.1.13 Glutathione Transferase Activity Targets
12.1.14 Growth factor activity Targets
12.1.15 Guanylate Cyclase Activity Targets
12.1.16 Hormone Activity Targets
12.1.17 Hydrolase Activity Targets
12.1.18 Kinase Activity Targets
12.1.19 Kinase Regulator Activity Targets
12.1.20 Ligase Activity Targets
12.1.21 Metallopeptidase Activity Targets
12.1.22 Molecular Function Unknown Targets
12.1.23 Motor Activity Targets
12.1.24 Oxidoreductase Activity Targets
12.1.25 Peptidase Activity Targets
12.1.26 Peroxidase Activity Targets
12.1.27 Protease Inhibitor Activity Targets
12.1.28 Protein Binding Targets
12.1.29 Protein Serine/Threonine Kinase Activity Targets
12.1.30 Protein Threonine/Tyrosine Kinase Activity Targets
12.1.31 Protein-Tyrosine Kinase Activity Targets
12.1.32 Receptor Activity Targets
12.1.33 Receptor Binding Targets
12.1.34 Receptor Signaling Complex Scaffold Activity Targets
12.1.35 Serine-Type Peptidase Activity Targets
12.1.36 Structural Constituent Of Cytoskeleton Targets
12.1.37 Transcription Factor Activity Targets
12.1.38 Transcription Regulator Activity Targets
12.1.39 Translation Regulator Activity Targets
12.1.40 Transmembrane Receptor Activity Targets
12.1.41 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
13 The Drug-Target Interactome
14 The Progression and Maturity of Colorectal Cancer Targets
14.1 Target Profiles of Colorectal Cancer Drugs in Pre-Registration to Marketed
14.2 New and Unique Colorectal Cancer Targets in Phase III Clinical Development
14.3 New and Unique Colorectal Cancer Targets in Phase II Clinical Development
14.4 New and Unique Colorectal Cancer Targets in Phase I Clinical Development
14.5 New and Unique Colorectal Cancer Targets in Preclinical Development
14.6 Development Profiles of All Colorectal Cancer Target Combinations
15 Targets by R&D Approach in Colorectal Cancer
15.1 Small Molecules
15.1.1 Background
15.1.2 Targets in Colorectal Cancer
15.2 Peptide/Protein Drugs
15.2.1 Background
15.2.2 Targets in Colorectal Cancer
15.3 Monoclonal Antibodies and Antibody-Like Structures
15.3.1 Background
15.3.2 Targets in Colorectal Cancer
15.4 Nucleic Acid Therapies
15.4.1 Background
15.4.2 Targets in Colorectal Cancer
15.5 Gene Therapy
15.5.1 Background
15.5.2 Targets in Colorectal Cancer
15.6 Drug Delivery and Nanotechnology
15.6.1 Background
15.6.2 Targets in Colorectal Cancer
16 Colorectal Cancer Targets by Companies
16.1 Australia
16.2 Canada
16.3 China
16.4 Cuba
16.5 Denmark
16.6 France
16.7 Germany
16.8 Israel
16.9 Italy
16.10 Japan
16.11 Netherlands
16.12 Norway
16.13 South Korea
16.14 Spain
16.15 Switzerland
16.16 Taiwan
16.17 United Kingdom
16.18 USA
16.19 Non-Industrial Bodies
17 Disclaimer
18 Drug Index
19 Company Index

4.1 List of Figures

Figure 1: Distribution of Compound Types among Colorectal Cancer Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Target-Target Interactions Among Colorectal Cancer Drug Targets
Figure 4: The Drug-Protein Interactome of Colorectal Cancer Drugs – The Main Cluster
Figure 5: The Drug-Protein Interactome of Colorectal Cancer Drugs – Smaller Clusters
Figure 6: Head-to-Head Targeting Interactome of Colorectal Cancer Drugs

4.2 List of Tables
Table 1: Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer Drug Targets
Table 2: Drug Targets of Colorectal Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Expression Levels of Identified Drug Targets in Colorectal Cancer Tissue
Table 4: Pathway Summary
Table 5: Drug Targets without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Colorectal Cancer Drug Targets
Table 7: Pathway Profile According to KEGG of Colorectal Cancer Drug Targets
Table 8: Pathway Profile According to NetPath of Colorectal Cancer Drug Targets
Table 9: Target-Target Interactions among Colorectal Cancer Drug Targets
Table 10: Identity of Colorectal Cancer Drug Targets with Available Biological Structures
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Interactome Clusters
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Top 5 Competitive Colorectal Cancer Targets
Table 15: Target Profiles of Colorectal Cancer Drugs in Pre-Registration to Marketed
Table 16: New and Unique Colorectal Cancer Targets in Phase III Clinical Development
Table 17: New and Unique Colorectal Cancer Targets in Phase II Clinical Development
Table 18 New and Unique Colorectal Cancer Targets in Phase I Clinical Development
Table 19: New and Unique Colorectal Cancer Targets in Preclinical Development
Table 20: The Progression, Maturity and Competitive Comparison of Colorectal Cancer Drug Targets in Development
Table 21: Number of Colorectal Cancer Drug Target Mixes Reported by Line of Therapy
Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Colorectal Cancer by Drug Target
Table 23: Drug Targets of Small Molecule Drugs in Colorectal Cancer
Table 24: Mechanistic Relationship between Small Molecule Drugs in Colorectal Cancer
Table 25: Drug Targets of Peptide Based Drugs in Colorectal Cancer
Table 26: Drug Targets of Protein Based Drugs in Colorectal Cancer
Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Colorectal Cancer
Table 28: Drug Targets of Nucleic Acid Therapies in Colorectal Cancer
Table 29: Vectors in Gene Therapy
Table 30: Drug Targets of Gene Therapies in Colorectal Cancer
Table 31: Drug Targets with New Drug Delivery Strategies in Colorectal Cancer
Table 32: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Australia
Table 33: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Canada
Table 34: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in China
Table 35: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Cuba
Table 36: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Denmark
Table 37: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in France
Table 38: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Germany
Table 39: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Israel
Table 40: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Italy
Table 41: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Japan
Table 42: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in the Netherlands
Table 43: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Norway
Table 44: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in South Korea
Table 45: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Spain
Table 46: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Switzerland
Table 47: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Taiwan
Table 48: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in United Kingdom
Table 49: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in USA
Table 50: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Non-Industrial Bodies

This report includes 108 investigators:
Abbott
Adherex
Alchemia
AlphaVax
Amgen
Antisense Pharma
Ariad
ARIUS Research
ArQule
Array BioPharma
AstraZeneca
Bayer
BioNumerik
Biorex Labs
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Can-Fite BioPharma
Celator Pharmaceuticals
Cell Therapeutics
Center of Molecular Immunology
CG Therapeutics
ChemGenex Pharmaceuticals
Chipscreen Biosciences
Choongwae
Clavis Pharma
CuraGen
Cyclacel
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
Dynavax Technologies
Eisai
Eli Lilly
Enkam Pharmaceuticals
Epeius Biotechnologies
Exelixis
Genentech
Genmab
Genta
GenVec
Genzyme
GlaxoSmithKline
GlycoGenesys
Green Cross
Hana Biosciences
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
ImClone Systems
Immunomedics
Incyte Corporation
Inovio
Introgen Therapeutics
Ipsen
ISU ABXIS
Johnson & Johnson
Kiadis
Kyowa Hakko
Lorus Therapeutics
Medarex
MediGene
Merck KGaA
MethylGene
Micromet
Mologen
NeoPharm
NicOx
Novartis
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
PDL BioPharma
Pfizer
PharmaEngine
PharmaMar
Plexxikon
Pro-Pharmaceuticals
Santaris Pharma
Shire
Sigma-Tau
Sonus Pharmaceuticals
SRI International
SuperGen
Taiho
Takeda
Targepeutics
Taxolog
Telik
Thallion Pharmaceuticals
TopoTarget
Trion Pharma
Vertex Pharmaceuticals
Wilex
VioQuest
Wyeth
Yakult Honsha
YM BioSciences
ZymoGenetics
This report includes 156 colorectal cancer drugs. From Preclinical to Marketed.
A shortlist of drugs included are:
bevacizumab
capecitabine
catumaxomab
cediranib
cetuximab
Davanat-2
doxifluridine
erlotinib
interferon(ß1a)
irinotecan hydrochloride
panitumumab
raltitrexed
sunitinib malate
tegafur + uracil
tegafur + uracil + leucovorin
TS-1
vatalanib

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis.
    To find out more about Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Melanoma Drug Pathway Analyzer
There are today at least 387 targeted molecular therapies known to affect more than 251 specific intracellular signaling pathways for the treatment of melanoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 283 drug targets that are included in this drug-pathway analyzing tool. No less than 265 of these have been recorded with mutations and 54 drug targets have mutations which have been causally implicated in cancer. Learn More